New NRF2 activators reported in Chugai Pharmaceutical patent

Aug. 7, 2023

Chugai Pharmaceutical Co. Ltd. has divulged nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NRF2) activators reported to be useful for the treatment of neurodegenerative, pulmonary and renal diseases.

BioWorld Science Neurology/psychiatric Patents

Today's news in brief

BioWorld

BioWorld briefs for Sept. 16, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for September 16, 2024.

3D illustration of T cells fighting cancer

Highfield Biopharmaceuticals files IND in China for immunoliposome HF-50 for solid tumors

BioWorld Science

Highfield Biopharmaceuticals Inc. has filed an IND application with China’s National Medical Products Administration (NMPA) to conduct a clinical trial of HF-50,...

Big pharma eyes China ‘at forefront of GLP-1 revolution’

BioWorld

Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes – Novo Nordisk A/S’s semaglutide (Wegovy/Ozempic) and Eli Lilly and...

Novo Nordisk seeks to repurpose GLP-1s, again, for the brain

BioWorld

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists (GLP-1RA) market for diabetes and...

Upgrade your daily dose of biopharma and medtech news

New NRF2 activators reported in Chugai Pharmaceutical patent